Pindolol

Single-blind cross-over study of 16 patients with mild to moderate hypertension treated with pindolol doses up to 20 mg daily, with 14 patients achieving adequate blood pressure control. The study demonstrated that pindolol can be effectively administered once daily with infrequent side effects.

Comprehensive review of multiple clinical trials across numerous countries demonstrating pindolol's antihypertensive efficacy, with 76% of patients achieving blood pressure normalization and 9% showing fair response. The drug proved effective in treating renal hypertension and was particularly useful in hypertensive patients with coexistent angina pectoris.

Pharmacological characterization of pindolol demonstrating its unique partial agonist activity on both beta-1 and beta-2 adrenoceptors, with relatively long duration of action and minimal first-pass hepatic metabolism. The partial agonist activity produces minimal alterations in normal cardiac output, heart rate, and peripheral blood flow, with reduced risk of rebound phenomena and bronchoconstriction compared to non-selective beta-blockers without intrinsic sympathomimetic activity.

Comprehensive review of multiple clinical trials across numerous countries demonstrating pindolol's antihypertensive efficacy, with 76% of patients achieving blood pressure normalization and 9% showing fair response. The drug proved effective in treating renal hypertension and was particularly useful in hypertensive patients with coexistent angina pectoris.

Pharmacological characterization of pindolol demonstrating its unique partial agonist activity on both beta-1 and beta-2 adrenoceptors, with relatively long duration of action and minimal first-pass hepatic metabolism. The partial agonist activity produces minimal alterations in normal cardiac output, heart rate, and peripheral blood flow, with reduced risk of rebound phenomena and bronchoconstriction compared to non-selective beta-blockers without intrinsic sympathomimetic activity.